Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda / Keytruda Qlex + paclitaxel
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with paclitaxel, with or without bevacizumab · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, a PD-L1 CPS of at least 1 on an FDA-authorized test, and one or two prior systemic regimens.
LAMPGEN ANALYSIS
Why it matters
PD-L1 status now identifies a treatment option in a defined platinum-resistant population. The option to include bevacizumab matters when describing the regimen and comparator.
What research teams should watch
Verify the PD-L1 result, prior lines and platinum resistance criteria. Maintain clear attribution when patients receive several agents with overlapping safety responsibilities.
PRIMARY RECORDS